SRAX Inc (SRAX): News: $SRAX NetworkNewsBreaks

News: $SRAX NetworkNewsBreaks - SRAX Inc. (NASDAQ: SRAX)

whytestocks · 2020-07-15T02:45:17.5000000Z

News: $SRAX NetworkNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Poised for Opportunity in the Business of Big Data SRAX (NASDAQ: SRAX) is positioned for opportunity in the business of big data, leveraging technology that unlocks information to reveal brands’ core consumers and their characteristics across several marketing channels. SRAX’s BIGtoken platform integrates all aspects of the adv... Got this from https://marketwirenews.com/news-releases/networknewsbreaks-srax-inc-nasdaq-srax-poised-for-op-8436504115457236.html?i=ib SRAX - NetworkNewsBreaks - SRAX Inc. (NASDAQ: SRAX) Poised for Opportunity in the Business of Big Data

Play Episode

5min

Proactive - Interviews for investors

Empire Metals MD on high-purity titanium breakthrough

Empire Metals Ltd (AIM:EEE) managing director Shaun Bunn talked with Proactive about the company's latest metallurgical test results at the Pitfield project. The test work delivered an impressive 91.6% purity titanium dioxide compound—achieved on the first attempt. Bunn emphasised that this high-grade product is free from deleterious contaminants, making it suitable for further processing into titanium sponge metal or premium-grade titanium pigments. He explained that the team successfully extracted and refined the titanium-bearing minerals using gravity separation, flotation, and acid digestion techniques. The company is now focused on optimising its processing flow sheet and scaling up test work. Recent bulk metallurgical sample collections at Pitfield will support larger-scale testing, with the goal of producing more of this high-grade product for market analysis. Bunn also highlighted that the simplicity of Pitfield's mineral composition, free from heavy metals or radioactive elements, has contributed to the rapid progress in refining processes. With further purification testing ahead, Empire Metals is poised to advance its titanium strategy. For more insights from this interview, visit Proactive’s YouTube channel. Don't forget to like, subscribe, and turn on notifications for future updates. #EmpireMetals #Titanium #Mining #PitfieldProject #Metallurgy #TitaniumDioxide #MineralProcessing #MiningStocks #TitaniumSponge #Investing

Proactive - Interviews for investors

Ilika CEO Graeme Purdy on 50Ah Goliath EV battery prototype milestone; scaling up

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy joined Proactive's Stephen Gunnion with details about the company's latest milestone—the successful prototyping of its 50Ah Goliath EV battery. This marks a significant leap from the previous 2Ah prototype, representing a 25-fold increase in capacity. Purdy highlighted the importance of scaling up production to meet industry requirements. "We need to make sure that we've got reproducibility. What industry needs is not just a few successful cells but large-scale, reliable production," he said. Ilika has benefited from £2.8 million in grant funding through the Faraday Battery Challenge, which Purdy noted has effectively doubled the impact of investor funding. In parallel, Ilika has also demonstrated its manufacturing process at a giga-scale setting through a partnership with the UK Battery Industrialisation Centre (UKBIC). Looking ahead, the company plans to complete its 1.5MWh per year pilot line with automated equipment. Key upcoming milestones include releasing P1.5 prototypes in the summer and the full P2 release by year-end. Stay tuned for more updates on Ilika’s Goliath program. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #IlikaPLC #EVBatteries #SolidStateBatteries #BatteryTechnology #EnergyStorage #RenewableEnergy #ElectricVehicles #BatteryInnovation #TechInvesting #ProactiveInvestors

Proactive - Interviews for investors

Europa Oil & Gas CEO on Cloughton planning application and community engagement

Europa Oil & Gas (Holdings) Plc (AIM:EOG) CEO Will Holland talked with Proactive's Stephen Gunnion about the company's submission of a planning application for the Cloughton appraisal well in Yorkshire. The application seeks approval to drill and test a gas field originally discovered in 1986. Holland explained that advancements in technology and improved gas prices now make it viable to extract gas at commercial rates. The appraisal well will determine the feasibility of full-field development. He also discussed the launch of a dedicated community engagement website, designed to provide local stakeholders with transparent information, including independent environmental and regulatory reports. Holland emphasised that the project follows strict UK regulations and aims to minimise environmental impact. Addressing concerns, he clarified that fracking is not involved, citing confirmation from Energy Minister Michael Shanks. He also noted that increased heavy goods vehicle (HGV) traffic would be minimal, at around 1% during operations. Holland stressed the project's potential benefits, including job creation and reducing the UK's reliance on imported liquefied natural gas (LNG). “If you're concerned about the environment, you should be supporting domestic gas production. And that's exactly what this is,” he stated. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for updates! #EuropaOilAndGas #EnergySecurity #NaturalGas #UKGas #CloughtonWell #EnergyTransition #Investing #OilAndGas #SustainableEnergy #LNG

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Followers	132
Posts	14996
Boards Moderated	0
Alias Born	06/04/2018

Volume:	-
Day Range:
Bid:	0.57
Ask:	0.5901
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SRAX Detailed Quote

Recent SRAX News

More SRAX News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SRAX News

Go Ad-Free